Latest Biotechnology, Pharmaceutical and Healthcare News from OncLive

05:10 EDT 16th July 2018 | BioPortfolio

Here are the most relevant search results for "OncLive" found in our extensive news archives from over 250 global news sources.

More Information about OncLive on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about OncLive for you to read. Along with our medical data and news we also list OncLive Clinical Trials, which are updated daily. BioPortfolio also has a large database of OncLive Companies for you to search.

Showing News Articles 1–25 of 707 from OncLive

Friday 13th July 2018

Oncology Groups Respond to CMS' Proposals for Payment Cuts

The Centers for Medicare & Medicaid Services has proposed a slate of changes that would reduce payment for some forms of patient evaluation and management and reduce the payment margin over wholesale acquisition cost for Medicare Part B drugs.

FDA Approves Enzalutamide for Nonmetastatic CRPC

The FDA has approved enzalutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer.  

Entrectinib May Have a Future Beyond Pediatric Relapsed/Refractory Solid Tumors

Ami Vijay Desai, MD, discusses the ideal patient population for entrectinib and what the future could hold for the agent.

Lead Author Reflects on LILAC Study of Trastuzumab Biosimilar ABP 980

Hans-Christian Kolberg, MD, discusses ABP 980 and the future of biosimilars in oncology.

PVd Regimen Highlighted as New Standard in Relapsed/Refractory Myeloma

Paul Richardson, MD, discusses the efficacy and tolerability of the combination of pomalidomide (Pomalyst), bortezomib (Velcade), and dexamethasone in patients with multiple myeloma.

Galsky Discusses Ongoing Combination Immunotherapy Trials in Bladder Cancer

Matthew Galsky, MD, discusses the IMvigor and CheckMate-901 studies 130, as well as the future for chemotherapy in bladder cancer.

State of Immunotherapy Continues to Shift in NSCLC

Liza C. Villaruz, MD, addresses the immunotherapy clinical trials that have informed the treatment of patients with NSCLC and the current state of biomarkers in the field.

Thursday 12th July 2018

Drake Discusses CARMENA Trial and Emerging Approaches in RCC

Charles G. Drake, MD, PhD, discusses the importance of the CARMENA results, the future of cytoreductive nephrectomy, and how the use of immunotherapy could change treatment in this setting.

MCL Researcher Highlights Future of CAR T-Cell Therapy, Other Approaches

Michael Wang, MD, discusses what he hopes to find in the ZUMA-2 trial and his belief that MCL can be cured in his lifetime.

Expert Stresses Importance of Genetic Testing in Ovarian Cancer

Deborah Krakow, MD, discusses the value of a patient’s family history and its implications on genetic counseling.

Expert Discusses Molecular Analysis and Treatment Options in Pediatric Ependymoma

Santhosh A. Upadhyaya, MD, discusses how chemotherapy prior to radiation can improve cure rates, the importance of long-term follow-up in this patient population, and emerging research and treatment for pediatric ependymoma.

FDA Approval Sought for Frontline Venetoclax Combo in AML

A supplemental New Drug Application has been submitted to the FDA for venetoclax (Venclexta) for use in combination with a hypomethylating agent or low-dose cytarabine for the first-line treatment of patients with acute myeloid leukemia. 

Pietras Presents Pillars of Palliative Care in Ovarian Cancer

Christopher J. Pietras, MD, discusses the elements of palliative care for patients with ovarian cancer.

Wednesday 11th July 2018

FDA Grants Pembrolizumab Priority Review for HCC

The FDA has granted a priority review designation to a supplemental biologics license application for pembrolizumab for previously treated patients with advanced hepatocellular carcinoma 

Antibody-Directed Therapeutic Research Ongoing in Ovarian Cancer

Sanaz Memarzadeh, MD, PhD, details the early developments of antibody-directed therapies and restoring p53 function in the treatment of patients with ovarian cancer.

Frontline Ibrutinib Plus R-CHOP Misses Primary Endpoint in Phase III DLBCL Trial

Combining ibrutinib with standard R-CHOP did not improve event-free survival versus R-CHOP alone in the first-line setting for patients with diffuse large B-cell lymphoma. 

Maintenance Ixazomib Improves PFS in Multiple Myeloma

Ixazomib (Ninlaro) improved progression-free survival compared with placebo as a maintenance therapy in adult patients with multiple myeloma who responded to high-dose therapy and autologous stem cell transplant.

Expert Tracks the Activity of PARP Inhibitors in Ovarian Cancer

Gottfried E. Konecny, MD, discusses developments in the understanding of response to PARP inhibition in ovarian cancer.

FDA Approves Nivolumab/Ipilimumab for MSI-H/dMMR Colorectal Cancer

The FDA has approved the combination of nivolumab and ipilimumab for the treatment of adult and pediatric patients 12 years and older with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.  

Tuesday 10th July 2018

PFS Valid Surrogate Endpoint for Overall Survival in Frontline DLBCL

Progression-free survival appears to be a surrogate endpoint for overall survival in patients undergoing firstline treatment for diffuse large B-cell lymphoma, according to results from a large pooled analysis.

Efforts Continue to Increase Immunotherapy Impact in Gynecologic Cancers

John A. Glaspy, MD, discusses challenges and progress with immunotherapy in gynecologic cancers.

Optimal Duration of Adjuvant Endocrine Therapy Undecided in ER+ Breast Cancer

Maryann J. Kwa, MD, discusses the optimal duration of endocrine therapy in the treatment of patients with early-stage ER-positive breast cancer.

Bauml Discusses State of Immunotherapy Biomarkers in NSCLC

Joshua Bauml, MD, discusses the limitations of PD-L1 and tumor mutational burden as immunotherapy biomarkers in non–small cell lung cancer and emerging biomarkers showing promise in the field.

Yu Shares Insight on Recent Advances in Castration-Sensitive Prostate Cancer

Evan Ya-Wen Yu, MD, discusses the evolution of treatment for patients with castration-sensitive prostate cancer and how he decides between treatment with abiraterone and docetaxel for this population.

Monday 9th July 2018

Palbociclib/Cetuximab Combo Highly Active in HPV-Unrelated HNSCC

The combination of the CDK4/6 inhibitor palbociclib and cetuximab induced an overall response rate of 39% in patients with platinum-resistant, HPV-unrelated recurrent/metastatic head and neck squamous cell carcinoma.

Quick Search


News Quicklinks